Literature DB >> 21478920

Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning.

S Yoshihara1, K Ikegame, K Taniguchi, K Kaida, E H Kim, J Nakata, R Kato, T Inoue, T Fujioka, H Tamaki, M Okada, T Soma, H Ogawa.   

Abstract

Graft failure is a major concern after cord blood transplantation (CBT) or HLA-haploidentical transplantation (haplo-SCT). As patients who undergo CBT or haplo-SCT almost always lack both matched-related and -unrelated donors, salvage transplantation would also be limited to either CBT or haplo-SCT. In this study, we assessed eight patients who received haplo-SCT as salvage therapy for graft failure. Five and three patients had received haplo-SCT and CBT, respectively, which resulted in graft failure. The median interval from the failed transplantation to salvage transplantation in six patients with primary graft failure was 33.5 days. The reduced-intensity conditioning regimen consisted of fludarabine, thiotepa, rabbit antithymocyte globulin and low-dose TBI. All eight patients achieved neutrophil engraftment, and seven patients achieved platelet recovery. The median times to neutrophil recovery and platelet recovery were 10 and 20 days, respectively. Three patients died from treatment-related causes: two from GVHD and one from rupture of carotid artery aneurysm. Five patients are alive, at a median follow-up of 946 days. The probability of overall survival at 5 years was 75%. These findings may serve as a rationale for giving precedence to haplo-SCT over CBT in salvage SCT after graft failure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21478920     DOI: 10.1038/bmt.2011.84

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

1.  Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients.

Authors:  B L Tang; X Y Zhu; C C Zheng; H L Liu; L Q Geng; X B Wang; K Y Ding; W Yao; J Tong; K D Song; L Zhang; P Qiang; Z M Sun
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

2.  Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies.

Authors:  H-L Liu; Z-M Sun; L-Q Geng; X-B Wang; K-Y Ding; J Tong; B-L Tang; C-Y Zhou; W Yao; C-C Zheng; K-D Song; X-Y Zhu; W Wei; Y Wang
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

3.  Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Authors:  Takumi Hoshino; Satoru Takada; Nahoko Hatsumi; Toru Sakura
Journal:  Int J Hematol       Date:  2019-02-08       Impact factor: 2.490

4.  Successful rescue of early graft failure in pediatric patients using T-cell-depleted haploidentical hematopoietic SCT.

Authors:  J A Park; K N Koh; E S Choi; S Jang; S W Kwon; C-J Park; J J Seo; H J Im
Journal:  Bone Marrow Transplant       Date:  2013-10-21       Impact factor: 5.483

5.  Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation.

Authors:  Kaito Harada; Shigeo Fuji; Sachiko Seo; Junya Kanda; Toshimitsu Ueki; Fumihiko Kimura; Koji Kato; Naoyuki Uchida; Kazuhiro Ikegame; Makoto Onizuka; Ken-Ichi Matsuoka; Noriko Doki; Toshiro Kawakita; Yasushi Onishi; Shingo Yano; Takahiro Fukuda; Minoko Takanashi; Yoshinobu Kanda; Yoshiko Atsuta; Masao Ogata
Journal:  Bone Marrow Transplant       Date:  2020-02-12       Impact factor: 5.483

6.  Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.

Authors:  J Kanda; M E Horwitz; G D Long; C Gasparetto; K M Sullivan; J P Chute; A Morris; T Hennig; Z Li; N J Chao; D A Rizzieri
Journal:  Bone Marrow Transplant       Date:  2011-08-01       Impact factor: 5.483

Review 7.  Recent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescents.

Authors:  Ho Joon Im; Kyung-Nam Koh; Jong Jin Seo
Journal:  Blood Res       Date:  2016-03-25

8.  Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis.

Authors:  Shuichiro Takahashi; Riko Tsumanuma; Keiko Aizawa; Mitsumasa Osakabe; Kunihiko Maeda; Ejiro Omoto
Journal:  Intern Med       Date:  2016-11-15       Impact factor: 1.271

9.  Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor.

Authors:  Yu-Qian Sun; Yu Wang; Feng-Rong Wang; Chen-Hua Yan; Yi-Fei Cheng; Yu-Hong Chen; Yuan-Yuan Zhang; Ting-Ting Han; Wei Han; Pan Suo; Lan-Ping Xu; Xiao-Hui Zhang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Front Med (Lausanne)       Date:  2021-06-04

10.  Haploidentical hematopoietic stem cell transplantation in a myelofibrosis patient with primary graft failure.

Authors:  Cristina Tecchio; Angelo Andreini; Claudio Costantini; Alberto Zamò; Donata de Sabata; Fiorenza Aprili; Roberta Galavotti; Emanuele Guardalben; Fabio Benedetti
Journal:  Hematol Rep       Date:  2018-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.